Intensive Monitoring Scheme of Lidocaine Cataplasms
Launched by QIANFOSHAN HOSPITAL · Dec 7, 2022
Trial Information
Current as of February 05, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients receiving Lidocaine Cataplasms from January 1, 2021 to April 1, 2022.
- Exclusion Criteria:
- • Unable to obtain complete medication information.
About Qianfoshan Hospital
Qianfoshan Hospital is a leading medical institution dedicated to advancing healthcare through innovative clinical research and trials. Located in Shandong Province, China, the hospital is renowned for its commitment to excellence in patient care and medical education. With a multidisciplinary team of experienced professionals, Qianfoshan Hospital focuses on a wide range of therapeutic areas, striving to enhance treatment options and improve patient outcomes. The institution actively collaborates with various stakeholders to ensure the highest standards of ethics and efficacy in its clinical research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jinan, Shandong, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials